mGlu2/3 Receptor Antagonists as Novel Antidepressants
Tóm tắt
Từ khóa
Tài liệu tham khảo
Rush, 2006, Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report, Am. J. Psychiatry, 163, 1905, 10.1176/ajp.2006.163.11.1905
Pilc, 2013, Glutamate-based antidepressants: preclinical psychopharmacology, Biol. Psychiatry, 73, 1125, 10.1016/j.biopsych.2013.01.021
Sanacora, 2008, Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders, Nat. Rev. Drug Discov., 7, 426, 10.1038/nrd2462
Berman, 2000, Antidepressant effects of ketamine in depressed patients, Biol. Psychiatry, 47, 351, 10.1016/S0006-3223(99)00230-9
Zarate, 2006, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression, Arch. Gen. Psychiatry, 63, 856, 10.1001/archpsyc.63.8.856
Krystal, 2013, Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond, Biol. Psychiatry, 73, 1133, 10.1016/j.biopsych.2013.03.026
Ionescu, 2016, Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study, J. Clin. Psychiatry, 77, e719, 10.4088/JCP.15m10056
Nakanishi, 1994, Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity, Neuron, 13, 1031, 10.1016/0896-6273(94)90043-4
Nicoletti, 2011, Metabotropic glutamate receptors: from the workbench to the bedside, Neuropharmacology, 60, 1017, 10.1016/j.neuropharm.2010.10.022
Durand, 2013, mGlu3 receptor and astrocytes: partners in neuroprotection, Neuropharmacology, 66, 1, 10.1016/j.neuropharm.2012.04.009
Aronica, 2005, Activation of metabotropic glutamate receptor 3 enhances interleukin (IL)-1beta-stimulated release of IL-6 in cultured human astrocytes, Neuroscience, 130, 927, 10.1016/j.neuroscience.2004.10.024
Chaki, 2013, mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants, Neuropharmacology, 66, 40, 10.1016/j.neuropharm.2012.05.022
Witkin, 2017, In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist, Neuropharmacology, 115, 100, 10.1016/j.neuropharm.2015.12.021
Chappell, 2016, Discovery of (1S,2R,3S,4S,5R,6R)-2-amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride (LY3020371·HCl): a potent, metabotropic glutamate 2/3 receptor antagonist with antidepressant-like activity, J. Med. Chem., 59, 10974, 10.1021/acs.jmedchem.6b01119
Campo, 2011, Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression, J. Neurogenet., 25, 152, 10.3109/01677063.2011.627485
Gleason, 2013, mGlu2/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2/3 receptor antagonism and its relation to antidepressant-like efficacy in mice, CNS Neurol. Disord. Drug Targets, 12, 554, 10.2174/18715273113129990079
Gregory, 2015, Molecular insights into metabotropic glutamate receptor allosteric modulation, Mol. Pharmacol., 88, 188, 10.1124/mol.114.097220
Lavreysen, 2013, Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782, J. Pharmacol. Exp. Ther., 346, 514, 10.1124/jpet.113.204990
Kingston, 1998, LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors, Neuropharmacology, 37, 1, 10.1016/S0028-3908(97)00191-3
Chaki, 2004, MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity, Neuropharmacology, 46, 457, 10.1016/j.neuropharm.2003.10.009
Yoshimizu, 2006, An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats, Psychopharmacology (Berl), 186, 587, 10.1007/s00213-006-0390-7
Pałucha-Poniewiera, 2010, On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039, Psychopharmacology (Berl), 212, 523, 10.1007/s00213-010-1978-5
Kawasaki, 2011, Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice, Neuropharmacology, 60, 397, 10.1016/j.neuropharm.2010.10.009
Feyissa, 2010, Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, 34, 279, 10.1016/j.pnpbp.2009.11.018
Muguruza, 2014, Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment, Neuropharmacology, 86, 311, 10.1016/j.neuropharm.2014.08.009
McOmish, 2016, Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia, J. Affect. Disord., 190, 241, 10.1016/j.jad.2015.10.004
Ago, 2013, Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice, Neuropharmacology, 65, 29, 10.1016/j.neuropharm.2012.09.008
Koike, 2013, Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats, Pharmacol. Biochem. Behav., 107, 20, 10.1016/j.pbb.2013.03.017
Witkin, 2016, The Rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits, J. Pharmacol. Exp. Ther., 358, 71, 10.1124/jpet.116.233627
Fukumoto, 2017, Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine, J. Pharmacol. Exp. Ther., 361, 9, 10.1124/jpet.116.239228
Dong, 2016, Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine, Int. J. Neuropsychopharmacol., 10.1093/ijnp/pyw089
Li, 2011, Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure, Biol. Psychiatry, 69, 754, 10.1016/j.biopsych.2010.12.015
Dwyer, 2013, mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure, J. Mol. Psychiatry, 1, 15, 10.1186/2049-9256-1-15
Popik, 2008, Lack of persistent effects of ketamine in rodent models of depression, Psychopharmacology (Berl), 198, 421, 10.1007/s00213-008-1158-z
Podkowa, 2016, Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats, Psychopharmacology (Berl), 233, 2901, 10.1007/s00213-016-4325-7
Podkowa, 2016, Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495, Neuropharmacology, 111, 169, 10.1016/j.neuropharm.2016.08.031
Engers, 2015, Discovery of a selective and CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 with antidepressant and anxiolytic activity in rodents, J. Med. Chem., 58, 7485, 10.1021/acs.jmedchem.5b01005
Nasca, 2015, Mind the gap: glucocorticoids modulate hippocampal glutamate tone underlying individual differences in stress susceptibility, Mol. Psychiatry, 20, 755, 10.1038/mp.2014.96
Nasca, 2013, L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors, Proc. Natl. Acad. Sci. U. S. A., 110, 4804, 10.1073/pnas.1216100110
Karasawa, 2005, AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist, Brain Res., 1042, 92, 10.1016/j.brainres.2005.02.032
Koike, 2014, Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats, Behav. Brain Res., 271, 111, 10.1016/j.bbr.2014.05.065
Alt, 2006, A role for AMPA receptors in mood disorders, Biochem. Pharmacol., 71, 1273, 10.1016/j.bcp.2005.12.022
Maeng, 2008, Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, Biol. Psychiatry, 63, 349, 10.1016/j.biopsych.2007.05.028
Popp, 2016, In search of the mechanisms of ketamine’s antidepressant effects: how robust is the evidence behind the mTor activation hypothesis, F1000Research, 5, 634, 10.12688/f1000research.8236.1
Autry, 2011, NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses, Nature, 475, 91, 10.1038/nature10130
Koike, 2011, Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists, Neuropharmacology, 61, 1419, 10.1016/j.neuropharm.2011.08.034
Koike, 2013, Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression, Behav. Brain Res., 238, 48, 10.1016/j.bbr.2012.10.023
Dwyer, 2012, mTOR activation is required for the antidepressant effects of mGluR2/3 blockade, Int. J. Neuropsychopharmacol., 15, 429, 10.1017/S1461145711001702
Lepack, 2016, Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures, Neuropharmacology, 111, 242, 10.1016/j.neuropharm.2016.09.011
Shirayama, 2006, Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents, Curr. Neuropharmacol., 4, 277, 10.2174/157015906778520773
Tye, 2013, Dopamine neurons modulate neural encoding and expression of depression-related behaviour, Nature, 493, 537, 10.1038/nature11740
Belujon, 2014, Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity, Biol. Psychiatry, 76, 927, 10.1016/j.biopsych.2014.04.014
Karasawa, 2006, A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell, Neurosci. Lett., 393, 127, 10.1016/j.neulet.2005.09.058
Karasawa, 2010, AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell, Neurochem. Int., 57, 615, 10.1016/j.neuint.2010.07.011
Witkin, 2017, Comparative effects of LY3020371, a potent and selective mGlu2/3 receptor antagonist, and ketamine, a non-competitive NMDA receptor antagonist, in rodents: evidence supporting use for the treatment of depression, J. Pharmacol. Exp. Ther., 61, 68, 10.1124/jpet.116.238121
Iijima, 2013, Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine, Behav. Brain Res., 246, 24, 10.1016/j.bbr.2013.02.039
Barr, 2002, A ‘crash’ course on psychostimulant withdrawal as a model of depression, Trends Pharmacol. Sci., 23, 475, 10.1016/S0165-6147(02)02086-2
Pehrson, 2014, Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction, CNS Spectr., 19, 121, 10.1017/S1092852913000540
Kawashima, 2005, Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors, Neurosci. Lett., 378, 131, 10.1016/j.neulet.2004.12.021
Fukumoto, 2016, The antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN, Neuropsychopharmacology, 41, 1046, 10.1038/npp.2015.233
Warden, 2012, A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge, Nature, 492, 428, 10.1038/nature11617
Brown, 1996, Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders, Am. J. Psychiatry, 153, 1293, 10.1176/ajp.153.10.1293
Fava, 2004, Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D, Psychol. Med., 34, 1299, 10.1017/S0033291704002612
Howland, 2009, Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome, Drug Alcohol Depend., 99, 248, 10.1016/j.drugalcdep.2008.08.010
Bespalov, 2008, Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression, Eur. J. Pharmacol., 592, 96, 10.1016/j.ejphar.2008.06.089
Shimazaki, 2004, Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test, Eur. J. Pharmacol., 501, 121, 10.1016/j.ejphar.2004.08.016
Iijima, 2007, Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice, Psychopharmacology (Berl), 190, 233, 10.1007/s00213-006-0618-6
Stachowicz, 2011, Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent, Pharmacol. Rep., 63, 880, 10.1016/S1734-1140(11)70603-X
Iijima, 2010, Effects of agents targeting glutamatergic systems on marble-burying behavior, Neurosci. Lett., 471, 63, 10.1016/j.neulet.2009.12.048
Schoepp, 2003, LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress, Stress, 6, 189, 10.1080/1025389031000146773
Dunayevich, 2008, Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder, Neuropsychopharmacology, 33, 1603, 10.1038/sj.npp.1301531
Hasselbalch, 2011, Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review, J. Affect. Disord., 134, 20, 10.1016/j.jad.2010.11.011
McIntyre, 2013, Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions, Depress. Anxiety, 30, 515, 10.1002/da.22063
Shimazaki, 2007, Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats, Eur. J. Pharmacol., 575, 94, 10.1016/j.ejphar.2007.08.006
Higgins, 2004, Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent, Neuropharmacology, 46, 907, 10.1016/j.neuropharm.2004.01.018
Goeldner, 2013, Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target, Neuropharmacology, 64, 337, 10.1016/j.neuropharm.2012.08.001
Ward, 2016, Pharmacological characterisation of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator, Br. J. Pharmacol., 174, 370, 10.1111/bph.13696
Koliaki, 2012, Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study, CNS Neurosci. Ther., 18, 302, 10.1111/j.1755-5949.2010.00244.x
McIntyre, 2016, The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials, Int. J. Neuropsychopharmacol., 19, pyw055, 10.1093/ijnp/pyw055
du Jardin, 2014, Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism, Eur. Neuropsychopharmacol., 24, 160, 10.1016/j.euroneuro.2013.07.001
Yoshimizu, 2004, Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039, Biochem. Biophys. Res. Commun., 315, 493, 10.1016/j.bbrc.2004.01.073
Duman, 2001, Regulation of adult neurogenesis by antidepressant treatment, Neuropsychopharmacology, 25, 836, 10.1016/S0893-133X(01)00358-X
Yasuhara, 2006, Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential, Bioorg. Med. Chem., 14, 4193, 10.1016/j.bmc.2006.01.060
Kim, 2014, Proneurogenic group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer mouse, Mol. Psychiatry, 19, 1235, 10.1038/mp.2014.87
Newcomer, 2001, NMDA receptor regulation of memory and behavior in humans, Hippocampus, 11, 529, 10.1002/hipo.1069
Witkin, 2017, Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects, Pharmacol. Biochem. Behav., 155, 43, 10.1016/j.pbb.2017.03.001